Galderma Laboratories, L.P. has announced that the US Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In